(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
| PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |
|---|---|---|---|---|---|---|---|
| 3fup | MI1 | Tofacitinib (DB08895) | Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatoid and psoriatic arthritis, and ulcerative colitis. It is not recommended to be combined with biologic therapies or potent immunosuppressants like cyclosporine or azathioprine. | TYROSINE-PROTEIN KINASE JAK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6vne | 2TA | Fedratinib (DB12500) | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was... | TYROSINE-PROTEIN KINASE JAK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6vsn | RG4 | Ruxolitinib (DB08877) | Ruxolitinib is a kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. | TYROSINE-PROTEIN KINASE JAK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| 6wto | 3JW | Baricitinib (DB11817) | Baricitinib is a Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. | TYROSINE-PROTEIN KINASE JAK2 (Homo sapiens) | PK_Tyr_Ser-Thr | ||
| PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |